Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TPM-1116
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Harmony Biosciences
Deal Size : $393.0 million
Deal Type : Licensing Agreement
Harmony Enters Agreement to Develop Oral Orexin-2 Agonist TPM-1116
Details : Through the Licensing Agreement, Bioprojet will develop, manufacture, and commercialize TPM-1116, a selective oral orexin-2 receptor agonist for narcolepsy and other sleep/wake disorders.
Product Name : TPM-1116
Product Type : Other Small Molecule
Upfront Cash : $25.5 million
November 04, 2024
Lead Product(s) : TPM-1116
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Harmony Biosciences
Deal Size : $393.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Wakix (pitolisant) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse.
Product Name : Wakix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioprojet: European Marketing Authorisation for OZAWADE™
Details : Ozawade (pitolisant hydrochloride) enhances the activity of histaminergic neurons, promotes wakefulness by blocking H3 autoreceptors and increases the levels of histamine transmitters at the synapse, and is used for Prader-Willi Syndrome.
Product Name : Ozawade
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable